Senti Biosciences Holdings, Inc. has implemented a 1-for-33 reverse stock split, effective November 18, 2026. This strategic decision aims to enhance the company's stock price and attractiveness to investors, reflecting a common practice in the biological products industry.

The company, incorporated in Delaware, operates in the biological products sector (SIC 2836) and is listed on the Nasdaq under the ticker symbol SNTI. Senti Biosciences has been active in the market, with several recent filings including a 10-Q on November 16, 2026, and an 8-K on November 10, 2026.

According to the SEC filing (accession number 0001628280-26-074812), the reverse stock split was approved by stockholders during the annual meeting held on October 8, 2026, and reconvened on October 15, 2026. The board of directors had the discretion to set the split ratio between 1-for-20 and 1-for-50, ultimately deciding on the 1-for-33 ratio.

The filing states that "every thirty-three shares of the Company’s Common Stock issued or outstanding were automatically reclassified into one validly issued, fully-paid and non-assessable new share of Common Stock." This adjustment is intended to improve the company's market position and make its shares more appealing to potential investors.

The reverse stock split will not affect the number of authorized shares or the par value of the common stock. Additionally, no fractional shares will be issued; instead, any fractional shares will be rounded up to the nearest whole share.

Trading of the adjusted shares will commence on a split-adjusted basis on November 19, 2026, under the existing trading symbol SNTI. The new CUSIP number for the common stock following the reverse split is 816944201.

As Senti Biosciences moves forward, the impact of this reverse stock split may resonate with its investors and competitors alike, as companies in the biological products industry often undertake similar measures to maintain competitiveness and market presence.

The filing does not specify what actions will follow this reverse stock split, leaving the future direction of the company open to speculation.